Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation NCT00911508

Patient Population:

  • 2,204 patients with paroxysmal atrial fibrillation
  • 18 to 90 yrs old

Trial Design: Randomized, open label, parallel assignment

Intervention: left atrial ablation versus rate or rhythm control medical therapy

Primary Endpoint: Composite of total mortality, disabling stroke, serious bleeding, or cardiac arrest

Sponsors: Mayo Clinic, NIH, NHLBI

Quality of Life Substudy

Principal Investigator:

Daniel B. Mark, MD

Primary QOL Measures:

  • Atrial Fibrillation Effect and Quality of Life (AFEQT) Scale
  • Mayo AF-Specific Symptom Inventory (MAFSI)

Other QOL Measures:

  • SF-36
  • Duke Activity Status Index (DASI)
  • Toronto Atrial Fibrillation Severity Score
  • EQ-5D-3L
  • Stanford Presenteeism Scale (SPS-6)
  • Work Productivity and Activity Impairment Questionnaire (WPAI)


Daniel Mark, MD presents the results of the quality of life substudy in the Trial to Assess Chelation Therapy.


The specific aim of the Quality of Life substudy of the CABANA trial is to compare health-related quality of life for atrial fibrillation versus rate or rhythm medical therapy.

The CABANA trial has presented the main clinical results at HRS 2018 and publication of the results is forthcoming.

See study website for more information.

The quality of life results were presented by Dr. Daniel Mark at the 2018 European Society of Cardiology Congress in Munich, Germany.

Dr. Jeanne Poole presented results on the recurrence of atrial fibrillation at the 2018 European Society of Cardiology Congress in Munich, Germany.

CABANA Publications

Awaiting trial results.

CABANA Trial Overview

January 12, 2012

Dr. Douglas Packer, CABANA PI, presents an overview of the CABANA trial.